MARKET

SLXN

SLXN

Silexion Therapeutics Corp
NASDAQ
0.2660
+0.0061
+2.35%
After Hours: 0.2550 -0.011 -4.14% 19:58 10/05 EDT
OPEN
0.2605
PREV CLOSE
0.2599
HIGH
0.2700
LOW
0.2570
VOLUME
1.23M
TURNOVER
--
52 WEEK HIGH
42.00
52 WEEK LOW
0.2362
MARKET CAP
1.53M
P/E (TTM)
-0.0047
1D
5D
1M
3M
1Y
5Y
1D
Silexion Therapeutics Begins Global SIL204 Pancreatic Cancer Trial
TipRanks · 5d ago
Silexion Doses First Patient In Phase 2/3 SIL204 Trial For Pancreatic Cancer
NASDAQ · 5d ago
Silexion announces first patient dosed in Phase 2/3 trial of SIL204
TipRanks · 5d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 5d ago
Silexion Therapeutics Announces First Patient Dosed Phase 2/3 Clinical Trial Evaluating Lead Candidate, SIL204, In Patients With Locally Advanced Pancreatic Cancer
Benzinga · 5d ago
Why FingerMotion Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Benzinga · 5d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 6d ago
Silexion Therapeutics Announces Warrant Inducement Financing Deal
TipRanks · 6d ago
More
About SLXN
Silexion Therapeutics Corp is an Israel-based oncology-focused biotechnology company. The Company is engaged in development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a preferred treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.

Webull offers Silexion Therapeutics Corp stock information, including NASDAQ: SLXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLXN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLXN stock methods without spending real money on the virtual paper trading platform.